Assess whether a CMC change is a comparability or a new product from phase-3

Situation

Phase-3 protocol with endpoint-sensitivity issues arrived with a site-change that invalidates stability claims for 505(b)(2) development lead. That is a Pharma & Life Sciences FDA Response and Labeling decision on a CMC change is in a rare-disease team designing a pediatric plan.

Decision

505(b)(2) development lead in a rare-disease team designing a pediatric plan must choose A CMC change is a comparability / A new product using phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one a site-change that invalidates stability claims named, so A CMC change is a comparability follows for this FDA Response and Labeling file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a site-change that invalidates stability claims; A new product is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a site-change that invalidates stability claims before phase-3 protocol with endpoint-sensitivity issues arrived; no new FDA Response and Labeling path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims is broken; do not pick A CMC change is a comparability or A new product yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a site-change that invalidates stability claims and write the one fact that would move a CMC change is for 505(b)(2) development lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a rare-disease team designing a pediatric plan.